Covered Drugs
20 manually verified drugs linked to the 2026 China NRDL & Commercial List launch sample.
Showing 20 of 20 drugs
| Generic / Chinese Name | Dosage Form | China Approval (NMPA) | 2026 Catalog Status | Verified |
|---|---|---|---|---|
| Mazdutide 玛仕度肽 · Xinermei / 信尔美 Endocrinology / Metabolic | Injection | Approved (Verified) H20250036, H20250037, H20250038 | NRDL 2026 Class B #30Announced · Effective Jan 1, 2027 | 2026-11-20 |
| Relmacabtagene autoleucel 瑞基奥仑赛 · Carteyva / 倍诺达 Oncology / Cell Therapy | Injection (CAR-T) | Approved (Verified) S20210035 | NRDL 2026 Class B #297Announced · Effective Jan 1, 2027 | 2026-11-20 |
| Insulin icodec / Semaglutide 依柯胰岛素司美格鲁肽 · IcoSema Endocrinology / Metabolic | Injection | NMPA Pending Backfill | NRDL 2026 Class B #18Announced · Effective Jan 1, 2027 | 2026-11-20 |
| Zolbetuximab 佐妥昔单抗 · Vyloy / 威络益 Oncology | Powder for Injection | Approved (Verified) SJ20240050 | NRDL 2026 Class B #287Announced · Effective Jan 1, 2027 | 2026-11-20 |
| Datopotamab deruxtecan 德达博妥单抗 · Datroway / 达卓优 Oncology | Powder for Injection | NMPA Pending Backfill | NRDL 2026 Class B #288Announced · Effective Jan 1, 2027 | 2026-11-20 |
| Sapropterin dihydrochloride 盐酸沙丙蝶呤 · 海普益 Rare Disease / Metabolic | Tablet | NMPA Pending Backfill | NRDL 2026 Class B #42Announced · Effective Jan 1, 2027 | 2026-11-20 |
| Pamiparib 帕米帕利 · Partruvix / 百汇泽 Oncology | Capsule | NMPA Pending Backfill | NRDL 2026 RemovedAnnounced · Effective Jan 1, 2027 | 2026-11-20 |
| Beraprost sodium (sustained-release) 贝前列素钠缓释片 Cardiovascular / Pulmonary | Sustained-Release Tablet | NMPA Pending Backfill | NRDL 2026 RemovedAnnounced · Effective Jan 1, 2027 | 2026-11-20 |
| Xiao'er Niuhuang Qingxin San 小儿牛黄清心散 Traditional Chinese Medicine | Oral Powder (TCM) | NMPA Pending Backfill | NRDL 2026 RemovedAnnounced · Effective Jan 1, 2027 | 2026-11-20 |
| Shenlong Ningxin Capsules 参龙宁心胶囊 Traditional Chinese Medicine | Capsule (TCM) | NMPA Pending Backfill | NRDL 2026 RemovedAnnounced · Effective Jan 1, 2027 | 2026-11-20 |
| Dupilumab 度普利尤单抗 · Dupixent / 达必妥 Immunology / Dermatology | Injection | NMPA Pending Backfill | NRDL 2026 Class B #104Announced · Effective Jan 1, 2027 | 2026-11-20 |
| Trastuzumab deruxtecan 德曲妥珠单抗 · Enhertu / 优赫得 Oncology | Powder for Injection | NMPA Pending Backfill | NRDL 2026 Class B #255Announced · Effective Jan 1, 2027 | 2026-11-20 |
| Sacituzumab tirumotecan 芦康沙妥珠单抗 · 佳泰莱 Oncology | Powder for Injection | Approved (Verified) S20240052 | NRDL 2026 Class B #284Announced · Effective Jan 1, 2027 | 2026-11-20 |
| Ivosidenib 艾伏尼布 · Tibsovo / 拓舒沃 Oncology / Hematology | Tablet | NMPA Pending Backfill | NRDL 2026 Class B #298Announced · Effective Jan 1, 2027 | 2026-11-20 |
| Eliglustat tartrate 酒石酸艾格司他 · Cerdelga / 赛德佳 Rare Disease / Metabolic | Capsule | NMPA Pending Backfill | NRDL 2026 Class B #41Announced · Effective Jan 1, 2027 | 2026-11-20 |
| Lutetium (177Lu) vipivotide tetraxetan 镥[177Lu]特昔维匹肽 · Pluvicto / 派威妥 Oncology / Radioligand | Injection | NMPA Pending Backfill | Commercial List #28Announced · Effective Jan 1, 2027 | 2026-11-20 |
| Tofersen 托夫生 · Qalsody / 凯盛迪 Neurology / Rare Disease | Injection | NMPA Pending Backfill | Commercial List #25Announced · Effective Jan 1, 2027 | 2026-11-20 |
| Eplontersen sodium 依普隆特生钠 · Wainua / 万诺维 Neurology / Rare Disease | Injection | NMPA Pending Backfill | Commercial List #24Announced · Effective Jan 1, 2027 | 2026-11-20 |
| Inaticabtagene autoleucel 纳基奥仑赛 · 源瑞达 Oncology / Cell Therapy | Injection | NMPA Pending Backfill | Commercial List #13Announced · Effective Jan 1, 2027 | 2026-11-20 |
| Tazemetostat hydrobromide 氢溴酸他泽司他 · Tazverik / 达唯珂 Oncology / Hematology | Tablet | NMPA Pending Backfill | 2025 Commercial List OnlyAnnounced · Effective Jan 1, 2027 | 2026-11-20 |